# Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

> **NCT00892437** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 85 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** COBI
- **DRUG:** RTV
- **DRUG:** ATV
- **DRUG:** FTC/TDF
- **DRUG:** COBI placebo
- **DRUG:** RTV placebo

## Key facts

- **NCT ID:** NCT00892437
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-12
- **Final completion:** 2015-01
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00892437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00892437, "Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00892437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*